Neurophth Closes RMB 400 Million Series B Financing

09 Feb, 2021

Neurophth Closes RMB 400 Million Series B Financing
Photo by Hunters Race on Unsplash

– Neurophth Biotechnology Ltd. announced the closing of a RMB 400 million ($61.9 million USD) Series-B financing with a premier syndicate of investors, co-led by Guofang Capital and InnoVision Capital.
– Neurophth is a fully-integrated genetic medicines company developing AAV-delivered gene therapies for the treatment of ocular diseases.
– The company has an extensive portfolio of potentially curative gene therapies for the treatment of ocular genetic diseases.

Asia Biotechnology Life Science
Crunchbase icon

Content report

The following text will be sent to our editors: